The invention relates to 17-(1′-propenyl)-17-3′-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the residues Z, R
4
, R
6a
, R
6b
, R
7
, R
15
, R
16a
, R
16b
and R
18
have the meanings stated in Claim
1,
and their solvates, hydrates and salts, including all stereoisomers of these compounds. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives, and in particular application in the aforementioned indications. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action.
该发明涉及具有通用
化学式I的17-(1'-
丙烯基)-17-3'-氧化酯基-4-烯-3-酮衍
生物,其中残基Z,R4,R6a,R6b,R7,R15,R16a,R16b和R18具有权利要求1中所述的含义,以及它们的溶剂合物,
水合物和盐,包括这些化合物的所有立体异构体。该发明还涉及利用这些衍
生物生产用于口服避孕和治疗围绝经期症状的药物产品,以及含有所述衍
生物的药物产品,并特别适用于上述适应症。根据本发明的衍
生物具有孕激素作用,并在优选情况下还具有抗矿物皮质激素和中性至轻微雄激素作用。